论文部分内容阅读
目的探讨研究治疗糖尿病肾病使用羟苯磺酸钙的临床治疗效果以及安全性。方法抽取自2016年3月至2017年1月来我院接受治疗糖尿病肾病的80例患者作为研究对象,随机分为观察组(40例)和对照组(40例)。对照组采用临床常规治疗,观察组则使用羟苯磺酸钙治疗,将两组患者的临床效果和安全性进行比较。结果观察组糖尿病肾病患者的24h尿蛋白定量、尿素氮、尿蛋白排泄率和血清肌酸酐明显优于对照组,差异具有统计学意义(P<0.05);观察组患者的治疗总有效率(87.2%)高于对照组患者的治疗总有效率(67.5%),差异具有统计学意义(P<0.05)。治疗后,两组患者均无不良反应。结论在治疗糖尿病肾病中使用羟苯磺酸钙能够有效的提高临床治疗效果,降低尿蛋白水平。
Objective To investigate the clinical efficacy and safety of research on calcium dobesilate in the treatment of diabetic nephropathy. Methods Eighty patients with diabetic nephropathy who were treated in our hospital from March 2016 to January 2017 were randomly divided into observation group (40 cases) and control group (40 cases). The control group was treated with routine clinical treatment while the observation group was treated with calcium dobesilate. The clinical efficacy and safety of the two groups were compared. Results The urinary protein excretion, urea nitrogen, urinary protein excretion rate and serum creatinine in diabetic nephropathy patients in observation group were significantly better than those in control group (P <0.05). The total effective rate in treatment group (87.2% %) Was higher than that of the control group (67.5%), the difference was statistically significant (P <0.05). After treatment, two groups of patients without adverse reactions. Conclusion The use of calcium dobesilate in the treatment of diabetic nephropathy can effectively improve the clinical therapeutic effect and reduce the level of urinary protein.